LEADER 05262nam 2200649Ia 450 001 9910830394403321 005 20230607213228.0 010 $a1-280-27001-2 010 $a9786610270019 010 $a0-470-36526-9 010 $a0-470-85419-7 010 $a0-470-85420-0 035 $a(CKB)111056485604306 035 $a(EBL)139832 035 $a(OCoLC)53880472 035 $a(SSID)ssj0000201562 035 $a(PQKBManifestationID)11201868 035 $a(PQKBTitleCode)TC0000201562 035 $a(PQKBWorkID)10245518 035 $a(PQKB)11112141 035 $a(MiAaPQ)EBC139832 035 $a(EXLCZ)99111056485604306 100 $a20020523d2002 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMeta-analysis of controlled clinical trials$b[electronic resource] /$fAnne Whitehead 210 $aChichester ;$aHoboken, NJ $cJohn Wiley & Sons$dc2002 215 $a1 online resource (353 p.) 225 1 $aStatistics in practice 300 $aDescription based upon print version of record. 311 0 $a0-471-98370-5 320 $aIncludes bibliographical references (p. 321-328) and index. 327 $aMeta-Analysis of Controlled Clinical Trials; Statistics in Practice; Contents; Preface; 1 Introduction; 1.1 The role of meta-analysis; 1.2 Retrospective and prospective meta-analyses; 1.3 Fixed effects versus random effects; 1.4 Individual patient data versus summary statistics; 1.5 Multicentre trials and meta-analysis; 1.6 The structure of this book; 2 Protocol development; 2.1 Introduction; 2.2 Background; 2.3 Objectives; 2.4 Outcome measures and baseline information; 2.5 Sources of data; 2.6 Study selection; 2.7 Data extraction; 2.8 Statistical analysis; 2.8.1 Analysis population 327 $a2.8.2 Missing data at the subject level 2.8.3 Analysis of individual trials; 2.8.4 Meta-analysis model; 2.8.5 Estimation and hypothesis testing; 2.8.6 Testing for heterogeneity; 2.8.7 Exploration of heterogeneity; 2.9 Sensitivity analyses; 2.10 Presentation of results; 3 Estimating the treatment difference in an individual trial; 3.1 Introduction; 3.2 Binary data; 3.2.1 Example: Stroke in hypertensive patients; 3.2.2 Measurement of treatment difference; 3.3 Survival data; 3.3.1 Example: Mortality following myocardial infarction; 3.3.2 Measurement of treatment difference 327 $a3.4 Interval-censored survival data 3.4.1 Example: Ulcer recurrence; 3.4.2 Measurement of treatment difference; 3.5 Ordinal data; 3.5.1 Example: Global impression of change in Alzheimer's disease; 3.5.2 Measurement of treatment difference; 3.6 Normally distributed data; 3.6.1 Example: Recovery time after anaesthesia; 3.6.2 Measurement of treatment difference; 4 Combining estimates of a treatment difference across trials; 4.1 Introduction; 4.2 A general fixed effects parametric approach; 4.2.1 A fixed effects meta-analysis model 327 $a4.2.2 Estimation and hypothesis testing of the treatment difference 4.2.3 Testing for heterogeneity across studies; 4.2.4 Obtaining the statistics via weighted least-squares regression; 4.2.5 Example: Stroke in hypertensive patients; 4.2.6 Example: Mortality following myocardial infarction; 4.2.7 Example: Ulcer recurrence; 4.2.8 Example: Global impression of change in Alzheimer's disease; 4.2.9 Example: Recovery time after anaesthesia; 4.3 A general random effects parametric approach; 4.3.1 A random effects meta-analysis model 327 $a4.3.2 Estimation and hypothesis testing of the treatment difference 4.3.3 Estimation of t(2) using the method of moments; 4.3.4 Obtaining the statistics via weighted least-squares regression; 4.3.5 Example: Mortality following myocardial infarction; 4.3.6 Example: Global impression of change in Alzheimer's disease; 4.3.7 Example: Recovery time after anaesthesia; 4.3.8 A likelihood approach to the estimation of t(2); 4.3.9 Allowing for the estimation of t(2); 5 Meta-analysis using individual patient data; 5.1 Introduction; 5.2 Fixed effects models for normally distributed data 327 $a5.2.1 A fixed effects meta-analysis model 330 $aOver the last twenty years there has been a dramatic upsurge in the application of meta-analysis to medical research. This has mainly been due to greater emphasis on evidence-based medicine and the need for reliable summaries of the vast and expanding volume of clinical research. At the same time there have been great strides in the development and refinement of the associated statistical methodology. This book describes the planning, conduct and reporting of a meta-analysis as applied to a series of randomized controlled clinical trials.* The various approaches are presented within a gene 410 0$aStatistics in practice. 606 $aClinical trials$xStatistical methods 606 $aMeta-analysis 615 0$aClinical trials$xStatistical methods. 615 0$aMeta-analysis. 676 $a610/.7/27 676 $a615.19 700 $aWhitehead$b Anne$0939635 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830394403321 996 $aMeta-analysis of controlled clinical trials$94050049 997 $aUNINA